Farrukh T. Awan
Abstract
In this issue of Blood, Thompson et al present their exciting long-term results with the use of fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL).1
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In this issue of Blood, Thompson et al present their exciting long-term results with the use of fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL).1
Key concepts: Chemoimmunotherapy, Fludarabine, Chronic lymphocytic leukemia, Rituximab, Medicine, Cyclophosphamide, Leukemia, Ibrutinib